RCUS
Arcus Biosciences, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +6.4% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 83 | +1 | 62.00M | $1.91B | +8 | −7 |
| Q1 2026 | 85 | -2 | 57.45M | $1.24B | +6 | −8 |
| Q4 2025 | 87 | -1 | 64.26M | $1.53B | +1 | −2 |
| Q3 2025 | 20 | +2 | 36.84M | $500.99M | +2 | — |
| Q2 2025 | 15 | -1 | 35.18M | $286.34M | — | −1 |
| Q1 2025 | 13 | +2 | 11.54M | $90.60M | +4 | −2 |
| Q4 2024 | 11 | 0 | 8.18M | $121.86M | +1 | −1 |
| Q3 2024 | 10 | 0 | 4.70M | $71.80M | — | — |
| Q2 2024 | 10 | — | 4.00M | $60.94M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 2.99M | — | $44.58M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Point72 Asset Management ✦ | 2.00M | -18.1% | $29.72M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.21M | -1.0% | $18.02M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.21M | -1.0% | $18.02M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Millennium Management ✦ | 924.37K | +277.1% | $13.76M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Adage Capital Partners ✦ | 443.00K | New | $6.60M | 0.0% | New | 1 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 360.59K | +13.4% | $5.37M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 360.59K | +13.4% | $5.37M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 146.69K | +8.1% | $2.18M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Norges Bank ✦ (passive) | 34.04K | -55.9% | $506,915 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 30.95K | -16.8% | $461,000 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 25.70K | -1.5% | $382,673 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 25.70K | -1.5% | $382,673 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 25.70K | -1.5% | $382,673 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 15 | Renaissance Technologies ✦ | 18.50K | -89.9% | $275,465 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Adage Capital Partners | $6.60M | 0.0% |
Exited
| D. E. Shaw & Co. | $206,430 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 209 holders, 119.00M shares, $2.56B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.83K sh · $84,810
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
24.7% of class · View original SEC filing ↗